Advertisement

Topics

EXSCEL: 'Disappointment' Spurs Discussion on GLP-1 Agonists in Diabetes

12:24 EDT 14 Sep 2017 | Medscape

Full details of EXSCEL with the GLP-1 agonist exenatide, in which the agent didn't show any cardiovascular benefit over placebo in type 2 diabetes, provide "some good news" but also "some disappointment."
Medscape Medical News

Original Article: EXSCEL: 'Disappointment' Spurs Discussion on GLP-1 Agonists in Diabetes

NEXT ARTICLE

More From BioPortfolio on "EXSCEL: 'Disappointment' Spurs Discussion on GLP-1 Agonists in Diabetes"

Quick Search
Advertisement
 

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...